Last reviewed · How we verify
NCT05041452
Multiparametric Cardio-hepatic MRI in Patients With Noncirrhotic Portal Hypertension
trial testing Cardiac magnetic resonance scan in Hypertension, Portal in 60 participants. Status unknown.
29 April 2022
Quick facts
| Lead sponsor | University Hospital, Bonn |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 29 April 2021 |
| Primary completion | 29 April 2022 |
| Estimated completion | 31 December 2023 |
| Sites | 2 locations across Germany |
Drugs / interventions tested
- Cardiac magnetic resonance scan
Conditions studied
- Hypertension, Portal — all drugs for Hypertension, Portal →
- Cardiomyopathies — all drugs for Cardiomyopathies →
Sponsor
University Hospital, Bonn
Who can join
Adults 18 to 60, any sex, with Hypertension, Portal or Cardiomyopathies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to use multiparametric MRI to investigate any differences in myocardial structure and function in patients with noncirrhotic portal hypertension compared with a control group with liver cirrhosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05041452
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cardiac magnetic resonance scan
Trials testing the same drug.
- NCT05034588 — Cardiac MRI for the Detection of Myocardial Injury Following Acute Kidney Injury · unknown
- NCT05041296 — Cardiac MRI for Detection of Acute and Chronic Cardiac Involvement in Patients With Epilepsy · unknown
Other recruiting trials for Hypertension, Portal
Currently open trials in the same condition.
- NCT07461545 — Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS · NA · recruiting
- NCT07461532 — Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD · NA · recruiting
- NCT07462091 — Vagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection · NA · recruiting
- NCT06437964 — Prophylactic Antibiotics in Endoscopic Secondary Prevention of Gastroesophageal Variceal Bleeding · NA · active not recruiting
- NCT04315571 — Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled E · NA · active not recruiting
Other University Hospital, Bonn trials
Trials by the same sponsor.
- NCT07291765 — Blood Flow Restriction Training in Acute Geriatric Rehabilitation: A Randomized Controlled Trial on Its Effects and Safe · NA · not yet recruiting
- NCT07324330 — Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity · NA · recruiting
- NCT07299591 — Analysis of Pharmacological Aspects Regarding Infection Free Survival After Surgical Treatment of a Periprosthetic Hip I · recruiting
- NCT07299565 — Analysis of Pharmacological Aspects Regarding Infection Free Survival After Surgical Treatment of a Periprosthetic Knee · recruiting
- NCT07043569 — Clinical-randomized Trial of the Effect of Rehabilitation Therapy Using Strength and Blood Flow Restriction Training on · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05041452 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Bonn
- Last refreshed: 13 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05041452.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing